Loading...

BioInvent International

DB:BIX
Snowflake Description

Exceptional growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BIX
DB
SEK510M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

BioInvent International AB (publ) focuses on the discovery and development of antibody-based drugs against cancer. The last earnings update was 22 days ago. More info.


Add to Portfolio Compare Print
  • BioInvent International has significant price volatility in the past 3 months.
BIX Share Price and Events
7 Day Returns
0%
DB:BIX
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-25.9%
DB:BIX
-5.6%
DE Biotechs
-4.5%
DE Market
BIX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BioInvent International (BIX) 0% -5.4% -36.5% -25.9% -45.4% -63.6%
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • BIX underperformed the Biotechs industry which returned -5.6% over the past year.
  • BIX underperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
BIX
Industry
5yr Volatility vs Market

Value

 Is BioInvent International undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for BioInvent International. This is due to cash flow or dividend data being unavailable. The share price is €0.106.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BioInvent International's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BioInvent International's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:BIX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in SEK SEK-0.36
OM:BINV Share Price ** OM (2019-04-25) in SEK SEK1.38
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BioInvent International.

DB:BIX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:BINV Share Price ÷ EPS (both in SEK)

= 1.38 ÷ -0.36

-3.8x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioInvent International is loss making, we can't compare its value to the Europe Biotechs industry average.
  • BioInvent International is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does BioInvent International's expected growth come at a high price?
Raw Data
DB:BIX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.8x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
105.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BioInvent International, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BioInvent International's assets?
Raw Data
DB:BIX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in SEK SEK0.25
OM:BINV Share Price * OM (2019-04-25) in SEK SEK1.38
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:BIX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:BINV Share Price ÷ Book Value per Share (both in SEK)

= 1.38 ÷ 0.25

5.52x

* Primary Listing of BioInvent International.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioInvent International is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess BioInvent International's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. BioInvent International has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is BioInvent International expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
105.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BioInvent International expected to grow at an attractive rate?
  • BioInvent International's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • BioInvent International's earnings growth is expected to exceed the Germany market average.
  • BioInvent International's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:BIX Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:BIX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 105.8%
DB:BIX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 56.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:BIX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:BIX Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 829 1
2021-12-31 509 1
2020-12-31 325 135 1
2019-12-31 75 -108 1
DB:BIX Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-12-31 39 -141 -123
2018-09-30 42 -126 -124
2018-06-30 42 -116 -123
2018-03-31 43 -175 -103
2017-12-31 45 -76 -101
2017-09-30 62 -76 -75
2017-06-30 56 -75 -82
2017-03-31 55 -81 -85
2016-12-31 71 -72 -63
2016-09-30 50 -59 -76
2016-06-30 51 -46 -70
2016-03-31 45 -50 -69

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BioInvent International's earnings are expected to grow significantly at over 20% yearly.
  • BioInvent International's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:BIX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from BioInvent International Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BIX Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31 0.39 0.39 0.39 1.00
2019-12-31 -0.31 -0.31 -0.31 1.00
DB:BIX Past Financials Data
Date (Data in SEK Millions) EPS *
2018-12-31 -0.36
2018-09-30 -0.38
2018-06-30 -0.39
2018-03-31 -0.34
2017-12-31 -0.33
2017-09-30 -0.25
2017-06-30 -0.27
2017-03-31 -0.28
2016-12-31 -0.25
2016-09-30 -0.35
2016-06-30 -0.38
2016-03-31 -0.42

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • BioInvent International is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess BioInvent International's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BioInvent International has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has BioInvent International performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BioInvent International's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BioInvent International does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare BioInvent International's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BioInvent International's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
BioInvent International's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BioInvent International Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BIX Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 38.55 -123.16 27.96 140.18
2018-09-30 41.71 -123.78 33.51 135.74
2018-06-30 41.80 -122.85 35.87 132.89
2018-03-31 43.37 -103.10 36.54 113.95
2017-12-31 45.01 -100.53 39.26 109.72
2017-09-30 62.27 -74.52 38.91 98.44
2017-06-30 55.94 -81.63 38.54 99.22
2017-03-31 54.88 -85.25 38.67 101.98
2016-12-31 71.28 -62.59 35.72 99.48
2016-09-30 50.48 -76.40 32.45 100.10
2016-06-30 51.34 -70.47 31.61 96.36
2016-03-31 44.69 -68.60 30.94 88.11
2015-12-31 15.93 -90.68 31.65 80.50
2015-09-30 7.61 -98.05 31.50 76.54
2015-06-30 17.00 -85.74 30.77 75.21
2015-03-31 45.78 -56.81 32.44 73.63
2014-12-31 46.93 -53.99 31.90 73.37
2014-09-30 95.24 -5.05 32.54 71.42
2014-06-30 92.01 -9.58 34.37 69.58
2014-03-31 71.84 -22.71 31.57 65.80
2013-12-31 81.71 -18.04 30.22 71.18
2013-09-30 41.03 -59.95 31.07 74.68
2013-06-30 46.10 -82.37 34.74 99.14
2013-03-31 40.08 -165.27 37.40 176.83
2012-12-31 42.95 -187.85 39.24 207.28
2012-09-30 35.48 -225.56 38.74 236.15
2012-06-30 29.76 -223.97 34.21 234.17

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BioInvent International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if BioInvent International has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if BioInvent International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess BioInvent International's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BioInvent International has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is BioInvent International's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BioInvent International's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BioInvent International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BioInvent International has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BioInvent International's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • BioInvent International has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BioInvent International Company Filings, last reported 3 months ago.

DB:BIX Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 87.62 0.00 68.85
2018-09-30 120.35 0.00 107.10
2018-06-30 142.54 0.00 144.70
2018-03-31 185.62 0.00 108.15
2017-12-31 130.23 0.00 133.76
2017-09-30 163.39 0.00 162.55
2017-06-30 184.60 0.00 192.77
2017-03-31 208.08 0.00 216.03
2016-12-31 230.44 0.00 226.11
2016-09-30 184.18 0.00 196.42
2016-06-30 212.69 0.00 224.46
2016-03-31 29.74 0.00 41.44
2015-12-31 29.45 0.00 39.97
2015-09-30 50.50 0.00 50.53
2015-06-30 73.10 0.00 62.71
2015-03-31 30.69 0.00 25.75
2014-12-31 52.43 0.00 45.63
2014-09-30 80.89 0.00 70.39
2014-06-30 91.16 0.00 74.30
2014-03-31 30.11 0.00 41.78
2013-12-31 49.01 0.00 64.75
2013-09-30 28.53 0.00 39.94
2013-06-30 23.96 0.00 39.76
2013-03-31 33.37 0.00 77.12
2012-12-31 47.62 0.00 100.06
2012-09-30 69.05 0.00 152.54
2012-06-30 106.37 0.00 186.25
  • BioInvent International has no debt.
  • BioInvent International has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • BioInvent International has less than a year of cash runway based on current free cash flow.
  • BioInvent International has less than a year of cash runway if free cash flow continues to grow at historical rates of 35.5% each year.
X
Financial health checks
We assess BioInvent International's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BioInvent International has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is BioInvent International's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BioInvent International dividends. Estimated to be 0% next year.
If you bought €2,000 of BioInvent International shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BioInvent International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BioInvent International's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:BIX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:BIX Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BioInvent International has not reported any payouts.
  • Unable to verify if BioInvent International's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BioInvent International's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BioInvent International has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of BioInvent International's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess BioInvent International's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BioInvent International afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BioInvent International has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of BioInvent International's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Martin Welschof
AGE 57
TENURE AS CEO 1.3 years
CEO Bio

Dr. Martin Welschof, Ph.D has been the Chief Executive Officer of Opsona Therapeutics Limited since February 2012. Dr. Welschof has been Chief Executive Officer at BioInvent Intl AB (publ) since 2018. He is also its President since September 01, 2018. Dr. Welschof served as a Key Consultant of Expres2ion Biotechnologies ApS. Dr. Welschof served as the Chief Operating Officer of Affitech AS and Affitech Research AS Oslo. He served as Managing Director of Affitech AS and Affitech Research AS Oslo from May 2010 to December 13, 2011. He Co-founded Affitech AS in 1995 and served as its Chief Technical Officer. Dr. Welschof served as the Chief Executive Officer of Affitech AS since 2003 for five years. Dr. Welschof served as Chief Operating Officer of Affitech AS from 2002 to 2003. After finishing his work at DKFZ where he established several important aspects of human antibody discovery systems, Dr. Welschof joined Axaron Bioscience AG, Heidelberg, Germany in 1999. Prior to joining Affitech AS, Dr. Welschof was Director of Technology at Axaron Bioscience AG from 1999 to 2002, where he joined in 1997 and he served as its Scientist and Project Leader from 1997 to 1999. Dr. Welschof oversaw the development of a large portfolio of cutting-edge technologies in the field of transcription analysis and functional genomics. He serves as Chairman of the Board of Directors of 4bio AS and Member of the Board of Directors of UniTargeting- Research AS. From 1999 to 2002, he led the technology department of Axaron and was responsible for the R&D process related to a large portfolio of cutting-edge technologies in the field of transcription analysis and functional genomics. During a portion of this period, he was an expatriate at the parent company of Axaron Bisoscience, LYNX Therapeutics Inc., where he was instrumental in co-ordinating the process development of LYNX massive parallel cloning and sequencing technologies MegaClone, MegaSort and MPSS. Dr. Welschof did his post-doctoral training at the German Cancer Research Center, Department for Recombinant Antibody Technology and at the University of Heidelberg, Department of Transplantation Immunology both in Heidelberg, Germany from 1996 to 1997. He was Research Fellow of DKFZ (German Cancer Research Centre)/Institute of Immunology (University of Heidelberg) and ZMBH (Centre for Molecular Biology Heidelberg) from 1992 to 1996 and 1991 to 1992 respectively. He was part of the core group in Prof. Melvyn Little's laboratory at the German Cancer Research Center during the development of the phage display technology. Dr. Welschof earned his Ph.D. in the field of recombinant antibody technology from the University of Bielefeld, Germany in 1996. He did his postdoctoral training at the German Cancer Research Center, Department for Recombinant Antibody Technology and at the University of Heidelberg, Department of Transplantation Immunology both in Heidelberg, Germany.

CEO Compensation
  • Insufficient data for Martin to compare compensation growth.
  • Insufficient data for Martin to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the BioInvent International management team in years:

2.4
Average Tenure
55
Average Age
  • The tenure for the BioInvent International management team is about average.
Management Team

Martin Welschof

TITLE
President & CEO
AGE
57
TENURE
1.3 yrs

Stefan Ericsson

TITLE
Chief Financial Officer
AGE
55
TENURE
3.3 yrs

Björn Frendéus

TITLE
Chief Scientific Officer
AGE
45

Kristoffer Hansson

TITLE
Senior Vice President of Technical Operations
AGE
44
TENURE
2.6 yrs

Andres McAllister

TITLE
Chief Medical Officer
AGE
62
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the BioInvent International board of directors in years:

2.3
Average Tenure
54
Average Age
  • The average tenure for the BioInvent International board of directors is less than 3 years, this suggests a new board.
Board of Directors

Leon Kruimer

TITLE
Chairman of the Board
COMPENSATION
SEK180K
AGE
60
TENURE
1.3 yrs

Kristoffer Bissessar

TITLE
Director
AGE
50
TENURE
1.3 yrs

Martin Glennie

TITLE
Chairman of the Scientific Advisory Board
TENURE
2.3 yrs

Dharminder Chahal

TITLE
Director
COMPENSATION
SEK169K
AGE
42
TENURE
2.3 yrs

Vessela Alexieva

TITLE
Employee Representative Director
AGE
59
TENURE
5.5 yrs

An van Johansson

TITLE
Director
COMPENSATION
SEK129K
AGE
58
TENURE
2.9 yrs

Vincent Ossipow

TITLE
Director
COMPENSATION
SEK129K
AGE
50
TENURE
2.9 yrs

Elin Gyllenbäck

TITLE
Employee Representative Director
AGE
39
TENURE
2.3 yrs

Bernd Seizinger

TITLE
Director
AGE
61
TENURE
1.3 yrs

Falk Nimmerjahn

TITLE
Member of Scientific Advisory Board
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
09. May 18 Buy Elin Gyllenbäck Individual 09. May 18 09. May 18 15,000 €0.18 €2,732
X
Management checks
We assess BioInvent International's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BioInvent International has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

BioInvent International AB (publ) focuses on the discovery and development of antibody-based drugs against cancer. The company’s lead drug candidate is BI-1206, a human antibody targeting CD32b, an immunosuppressive protein that is expressed in patients with B-cell cancers. The BI-1206 drug is in Phase I/II clinical trials currently ongoing in patients with non-Hodgkin lymphoma and chronic lymphocytic leukaemia who are resistant to rituximab. The company has a collaboration agreement with Oncurious BV to develop TB-403, a humanized antibody directed against the PlGF protein, which is in Phase I/II clinical trials used for the treatment of patients with medulloblastoma; and with ThromboGenics to develop THR-317 that is in Phase I/II clinical trials used for the treatment of patients with diabetic macular edema. It is also developing immuno-modulatory antibodies, such as cancer-associated regulatory T cells and tumour-associated myeloid-derived suppressor cells. The company has a research collaboration and license agreement with Pfizer Inc. for the development of antibodies against tumour-associated myeloid cells. In addition, it has research collaborations with Bayer Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Servier, Xoma, and Transgene, as well as University of Southampton, Cancer Research UK, Lund University, and Penn Medicine. BioInvent International AB (publ) also has a collaboration with Transgene SA to co-develop multi-functional oncolytic viruses encoding for undisclosed antibodies sequences for treating a range of solid tumors. The Company was founded in 1997 and is based in Lund, Sweden.

Details
Name: BioInvent International AB (publ)
BIX
Exchange: DB
Founded: 1997
SEK48,038,383
369,549,972
Website: http://www.bioinvent.com
Address: BioInvent International AB (publ)
The Gamma Building,
Sölvegatan 41,
Lund,
223 70,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM BINV Ordinary Shares OMX Nordic Exchange Stockholm SE SEK 14. Jun 2001
OTCPK BOVN.F Ordinary Shares Pink Sheets LLC US USD 14. Jun 2001
DB BIX Ordinary Shares Deutsche Boerse AG DE EUR 14. Jun 2001
LSE 0H22 Ordinary Shares London Stock Exchange GB SEK 14. Jun 2001
BATS-CHIXE BINVS Ordinary Shares BATS 'Chi-X Europe' GB SEK 14. Jun 2001
OM BINV BTA SHS OMX Nordic Exchange Stockholm SE SEK 29. Mar 2019
Number of employees
Current staff
Staff numbers
62
BioInvent International employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 21:09
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/24
Last earnings filing: 2019/04/03
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.